US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

F/m Emerald Life Sciences Innovation ETF

45.83

+0.50251.11%

Post-market: 45.33-0.5025-1.10%19:30 EDT

Volume:419

Turnover:19.22K

Market Cap:129.10M

PE:- -

High:45.83

Open:45.33

Low:45.83

Close:45.33

52wk High:48.78

52wk Low:27.68

Shares:2.82M

Float Shares:2.82M

Volume Ratio:0.17

T/O Rate:0.01%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Structure Therapeutics reports ACCG-2671, aleniglipron trial results

Guardant Health Price Target Announced at $203.00/Share by Rothschild & Co

Spyre Therapeutics announces 12-week induction data from Part A of SKYLINE trial

Spyre Reports Positive Phase 2 Skyline Part a Induction Data for UC Drug Spy003, Hits Primary Endpoint

Spyre Therapeutics - Spy003 Meets Primary Endpoint with 10.0-Point Rhi Reduction at Week 12

THOMSON REUTERS

Spyre Therapeutics - Spy003 Well Tolerated with Safety Profile Consistent with Il-23 Class

THOMSON REUTERS

Spyre Therapeutics - Spy003 Achieves 20% Clinical Remission and 30% Endoscopic Improvement at Week 12

THOMSON REUTERS

Spyre Therapeutics - Skyline Part B Enrolling; Topline Induction Data Expected in 2027

THOMSON REUTERS

Guardant Health's Breast Cancer Diagnostic Approved by US FDA

MT Newswires Live

Rothschild & Co Redburn Initiates Guardant Health at Buy

MT Newswires Live

Guardant Health initiated with a Buy at Rothschild & Co Redburn

Milton Essex boosts Sanford Biotech capital to drive advanced mastitis cell therapy

Guardant announces FDA approval of Guardant360 CDx as companion diagnostic

Guardant Health Announces Landmark FDA Approval of Guardant360® Cdx as Companion Diagnostic for AstraZeneca’s Etcamah™ (Camizestrant) in Advanced Breast Cancer

THOMSON REUTERS

Spyre Therapeutics Grants Inducement Awards of 2,106 Stock Options, 745 RSUs to New Employee

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics CEO Turtle Cameron Disposes of 15,000 Common Shares Worth $1.31 Million

LivaNova Presents at Morgan Stanley Global Healthcare Conference

LivaNova Files Form 3 for Chief Legal Officer Anne M. Liddy

LivaNova Director Francesco Bianchi Sells 1,650 Shares for $131,538

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/LFSC/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LFSC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","market":"US","secType":"STK","nameCN":"F/m Emerald Life Sciences Innovation ETF","latestPrice":45.83,"timestamp":1789416000000,"preClose":45.3275,"halted":0,"volume":419,"hourTrading":{"tag":"盘后","latestPrice":45.3275,"preClose":45.83,"latestTime":"19:30 EDT","volume":11,"amount":503.73,"timestamp":1789428605536,"change":-0.5025,"changeRate":-0.010964,"amplitude":0},"delay":0,"changeRate":0.01108598532899449,"floatShares":2817035,"shares":2817035,"eps":0,"marketStatus":"Not Yet Opened","change":0.5025,"latestTime":"09-14 16:00:00 EDT","open":45.3275,"high":45.83,"low":45.83,"amount":19220.873733,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789459200000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":45.3275,"sharesOutstanding":2657035,"nav":45.28,"aum":127555344.8,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":45.3275,"preClose":45.83,"latestTime":"19:30 EDT","volume":11,"amount":503.73,"timestamp":1789428605536,"change":-0.5025,"changeRate":-0.010964,"amplitude":0},"volumeRatio":0.167976},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","floatShares":2817035,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.167976,"shares":2817035,"dividePrice":0,"high":45.83,"amplitude":0,"preClose":45.3275,"low":45.83,"week52Low":27.6794,"pbRate":"--","week52High":48.78,"institutionHeld":0,"latestPrice":45.83,"eps":0,"divideRate":0,"volume":419,"delay":0,"ttmEps":0,"open":45.3275,"prevYearClose":36.6147,"prevWeekClose":45.3275,"prevMonthClose":45.79,"prevQuarterClose":45.2033,"fiveDayClose":46.1341,"twentyDayClose":47.0833,"sixtyDayClose":40.7444},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LFSC\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LFSC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LFSC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LFSC\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665637847","title":"Structure Therapeutics reports ACCG-2671, aleniglipron trial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2665637847","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665637847?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:36","pubTimestamp":1788871007,"startTime":"0","endTime":"0","summary":"Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates: ACCG-2671, an oral, non-peptide, small molecule...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRNY","SBIO","GSKH","FHLC","IBBQ","BME","MDTX","RSPH","LLYX","CNCR","CURE","PBE","PJP","JDOC","IBBJ","BIB","CANC","LFSC","SYNB","FTXH","JHMH","PTH","IBRN","BBH","GPCR","TBXU","WDNA","PBPH","NVIB","HYLG","PSCH","SURI","PSIL","IBB","MEDI","BBP","FBT","PINK","FXH","MEDX","MNTL","HRTS","XPH","AZNH","GNMX","APXH","LENZ","GDOC","GNOM","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665378332","title":"Guardant Health Price Target Announced at $203.00/Share by Rothschild & Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2665378332","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665378332?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:26","pubTimestamp":1788870360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GH/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","GNMX","LU0889565916.HKD","LU0320765992.SGD","GNOM","BK4585","EKG","FFOX","BK4551","GDOC","BK4588","GH","HELX","BK4196","PTH","BK4535","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320733","title":"Spyre Therapeutics announces 12-week induction data from Part A of SKYLINE trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320733","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320733?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:15","pubTimestamp":1788869740,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics (SYRE) announced positive 12-week induction data from Part A of the Phase 2 SKYLINE trial of SPY003, an anti-IL-23 being investi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-announces-12-week-induction-data-from-part-a-of-skyline-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-announces-12-week-induction-data-from-part-a-of-skyline-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","LFSC","LENZ","SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320564","title":"Spyre Reports Positive Phase 2 Skyline Part a Induction Data for UC Drug Spy003, Hits Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320564","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320564?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:01","pubTimestamp":1788868896,"startTime":"0","endTime":"0","summary":"Spyre reports positive Phase 2 SKYLINE Part A induction data for UC drug SPY003, hits primary endpointSpyre Therapeutics reported positive 12-week induction results from Part A of its Phase 2 SKYLINE ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL1KRyb1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","IE00B3QW5Z07.USD","LFSC","IE00B64PRP62.GBP","IE00BQXX3F31.USD","IE00BKPKM429.USD","BCDF","BK4585","IE00BQXX3C00.GBP","BK4112","LU0314104364.USD","SG9999014021.USD","IE00BN0W2W23.USD","LU2210149790.SGD","SG9999014013.SGD","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","BK4139","BK4588","IE00BQXX3D17.EUR","SG9999014005.SGD","SG9999014039.USD","NDAQ","LU2210150020.SGD","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665544320","title":"Spyre Therapeutics - Spy003 Meets Primary Endpoint with 10.0-Point Rhi Reduction at Week 12","url":"https://stock-news.laohu8.com/highlight/detail?id=2665544320","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665544320?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:00","pubTimestamp":1788868808,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA7PFYB1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LFSC","SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320546","title":"Spyre Therapeutics - Spy003 Well Tolerated with Safety Profile Consistent with Il-23 Class","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320546","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320546?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:00","pubTimestamp":1788868808,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA7PFYB1:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","LFSC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320514","title":"Spyre Therapeutics - Spy003 Achieves 20% Clinical Remission and 30% Endoscopic Improvement at Week 12","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320514","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320514?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:00","pubTimestamp":1788868808,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA7PFYB1:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","LFSC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665205113","title":"Spyre Therapeutics - Skyline Part B Enrolling; Topline Induction Data Expected in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2665205113","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665205113?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:00","pubTimestamp":1788868808,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA7PFYB1:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LFSC","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665321994","title":"Guardant Health's Breast Cancer Diagnostic Approved by US FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2665321994","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665321994?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:08","pubTimestamp":1788862114,"startTime":"0","endTime":"0","summary":"Guardant Health's  Guardant360 CDx has been approved by the US Food and Drug Administration as a companion diagnostic for advanced metastatic breast cancer, the company said Friday.The specific indication for the diagnostic combination is to identify patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer harboring tumors with specific mutations before radiographic progression who may benefit from treatment with AstraZeneca's  Etcamah, the company said.The approval is based on data from a clinical trial showing a 56% reduction in the risk of progression or death, the company said.Shares of the company were up 1% in recent premarket trading.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2237443895.HKD","AZN","HELX","LU2456880835.USD","LU2462157665.USD","LU0708994859.HKD","AZNH","LU0109394709.USD","LU0289739699.SGD","LU2468319806.SGD","GH","LU0128525929.USD","LU2089984988.USD","LABU","LU2236285917.USD","LU0310800379.SGD","EKG","LU1267930573.SGD","GDOC","LU0320765992.SGD","LU0029864427.USD","FFOX","GNMX","LFSC","LU2237443622.USD","PTH","BK4551","BK4585","LU0432979614.USD","BK4568","LU2237443978.SGD","GNOM","LU0889565916.HKD","LU2417539215.USD","LU1829250122.USD","LU0058720904.USD","BK4007","LU2237443549.SGD","BK4535","BK4196","LU2237443465.HKD","LU2237443382.USD","IE00B3T34201.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665213403","title":"Rothschild & Co Redburn Initiates Guardant Health at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2665213403","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665213403?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:01","pubTimestamp":1788861705,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) has an average rating of buy and mean price target of $198.38, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GNOM","LU0109394709.USD","BK4196","GH","LFSC","GDOC","LU0320765992.SGD","GNMX","FFOX","PTH","BK4585","LU0889565916.HKD","EKG","BK4551","BK4535","HELX","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665532615","title":"Guardant Health initiated with a Buy at Rothschild & Co Redburn","url":"https://stock-news.laohu8.com/highlight/detail?id=2665532615","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665532615?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:16","pubTimestamp":1788858969,"startTime":"0","endTime":"0","summary":"Rothschild & Co Redburn initiated coverage of Guardant Health (GH) with a Buy rating and $203 price target The firm says Guardant is the leader in ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-health-initiated-with-a-buy-at-rothschild-co-redburn-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-health-initiated-with-a-buy-at-rothschild-co-redburn-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","FFOX","GNMX","LFSC","HELX","PTH","BK4551","BK4585","GNOM","BK4535","LU0109394709.USD","EKG","BK4196","GH","GDOC","LU0320765992.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665101723","title":"Milton Essex boosts Sanford Biotech capital to drive advanced mastitis cell therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2665101723","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665101723?lang=en_us&edition=fundamental","pubTime":"2026-09-08 02:47","pubTimestamp":1788806848,"startTime":"0","endTime":"0","summary":"MILTON ESSEX S.A. ( ($PL:MTN) ) just unveiled an announcement. Milton Essex S.A., acting as sole shareholder of Sanford Biotech, has approved a PLN...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/milton-essex-boosts-sanford-biotech-capital-to-drive-advanced-mastitis-cell-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/milton-essex-boosts-sanford-biotech-capital-to-drive-advanced-mastitis-cell-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","CNCR","LFSC","IBBQ","IBB","TBXU","GNOM","BK4581","MTNmain","SYNB","BK4588","FBT","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665354019","title":"Guardant announces FDA approval of Guardant360 CDx as companion diagnostic","url":"https://stock-news.laohu8.com/highlight/detail?id=2665354019","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665354019?lang=en_us&edition=fundamental","pubTime":"2026-09-05 06:15","pubTimestamp":1788560112,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) announced that the U.S. Food and Drug Administration has approved Guardant360 CDx as a companion diagnostic to identify patien...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-announces-fda-approval-of-guardant360-cdx-as-companion-diagnostic-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-announces-fda-approval-of-guardant360-cdx-as-companion-diagnostic-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IYH","TBXU","XLVX","BK4585","EKG","PSCH","LU0889565916.HKD","IBB","GNOM","BK4551","NVIB","LU0320765992.SGD","FRTY","IEIH","BK4588","PTH","IDNA","PINK","LABU","LFSC","FFOX","GH","HELX","SYNB","BMED","TECB","MRNY","MEDI","BK4535","BK4196","GNMX","BBP","LU0109394709.USD","RSPH","GDOC","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665354794","title":"Guardant Health Announces Landmark FDA Approval of Guardant360® Cdx as Companion Diagnostic for AstraZeneca’s Etcamah™ (Camizestrant) in Advanced Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2665354794","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665354794?lang=en_us&edition=fundamental","pubTime":"2026-09-05 06:10","pubTimestamp":1788559800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nTUA7GZLSJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","BK4535","BK4196","BK4551","FFOX","EKG","GH","HELX","BK4585","LU0320765992.SGD","GDOC","GNOM","LU0109394709.USD","PTH","BK4588","LFSC","GNMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665359486","title":"Spyre Therapeutics Grants Inducement Awards of 2,106 Stock Options, 745 RSUs to New Employee","url":"https://stock-news.laohu8.com/highlight/detail?id=2665359486","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665359486?lang=en_us&edition=fundamental","pubTime":"2026-09-05 04:01","pubTimestamp":1788552087,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics grants inducement awards of 2,106 stock options, 745 RSUs to new employeeSpyre Therapeutics granted inducement equity awards to one non-executive employee under its 2018 Equity Indu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nNDL2lPXJr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","IE00BQXX3D17.EUR","IE00BN0W2V16.EUR","BK4588","LU2210150020.SGD","SG9999014013.SGD","IE00BN0W2W23.USD","BK4585","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4139","SYRE","SG9999014039.USD","BK4112","NDAQ","LU2095319765.USD","IE00BN0W2T93.GBP","IE00BQXX3F31.USD","IE00B3QW5Z07.USD","BCDF","IE00BQXX3C00.GBP","LU0314104364.USD","IE00BKPKM429.USD","SG9999014005.SGD","LU2210149790.SGD","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665351482","title":"Spyre Therapeutics Announces Grants of Inducement Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2665351482","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665351482?lang=en_us&edition=fundamental","pubTime":"2026-09-05 04:01","pubTimestamp":1788552060,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Sept.  04, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/04/3356774/0/en/spyre-therapeutics-announces-grants-of-inducement-awards.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4539","BK4007","BK4139","LFSC","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664388298","title":"Spyre Therapeutics CEO Turtle Cameron Disposes of 15,000 Common Shares Worth $1.31 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2664388298","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664388298?lang=en_us&edition=fundamental","pubTime":"2026-09-04 09:33","pubTimestamp":1788485613,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics CEO Turtle Cameron disposes of 15,000 common shares worth $1.31 millionSpyre Therapeutics CEO Turtle Cameron sold 15,000 common shares on Sep. 1, 2026 at weighted-average prices of ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nNDL63hWDH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Spyre Therapeutics CEO Turtle Cameron Disposes of 15,000 Common Shares Worth $1.31 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","LFSC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664687247","title":"LivaNova Presents at Morgan Stanley Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2664687247","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664687247?lang=en_us&edition=fundamental","pubTime":"2026-09-03 21:02","pubTimestamp":1788440554,"startTime":"0","endTime":"0","summary":"LivaNova presents at Morgan Stanley Global Healthcare ConferenceLivaNova will present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Sept. 14.The company will also prese","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL1k8m7D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1791710400.SGD","IAI","LU2264538146.SGD","LU0158827948.USD","LU0314104364.USD","LU1668664300.SGD","LU0795875086.SGD","LU0912757837.SGD","LU1791710582.SGD","LU0320765646.SGD","LU0006306889.USD","LU0557290698.USD","LFSC","LU1720051017.SGD","LU1363072403.SGD","KBWB","LU1732800096.USD","LU0795875169.SGD","LU0234570918.USD","LU1244550221.USD","LU2065169927.USD","LU2089283258.USD","LU0158827781.USD","IE00BZ1G4Q59.USD","LIVN","LU1988902786.USD","LU1064131342.USD","BK4588","LU0225283273.USD","LU2089284900.SGD","LU0882574139.USD","LU2023251221.USD","LU1720051108.HKD","LU2271345857.HKD","LU0210528500.USD","LU2065170008.USD","LU0390134368.USD","BK4082","LU0098860793.USD","LU1548497426.USD","BK4581","LU1244550494.USD","LU2111349929.HKD","LU0053666078.USD","LU2065171311.SGD","LU2065171402.SGD","LU2028103732.USD","LU2133065610.SGD","LU0106831901.USD","LU1074936037.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664849214","title":"LivaNova Files Form 3 for Chief Legal Officer Anne M. Liddy","url":"https://stock-news.laohu8.com/highlight/detail?id=2664849214","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664849214?lang=en_us&edition=fundamental","pubTime":"2026-09-03 04:20","pubTimestamp":1788380419,"startTime":"0","endTime":"0","summary":"LivaNova files Form 3 for Chief Legal Officer Anne M. LiddyLivaNova filed an initial Form 3 for Chief Legal Officer Anne M. Liddy, dated Aug. 31, 2026.Disclaimer:This news brief was created by Public ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL4FZGNq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","BK4082","LU2065170008.USD","LU2065171311.SGD","LU2065169927.USD","LU2065171402.SGD","LIVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664984921","title":"LivaNova Director Francesco Bianchi Sells 1,650 Shares for $131,538","url":"https://stock-news.laohu8.com/highlight/detail?id=2664984921","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664984921?lang=en_us&edition=fundamental","pubTime":"2026-09-03 04:20","pubTimestamp":1788380413,"startTime":"0","endTime":"0","summary":"LivaNova director Francesco Bianchi sells 1,650 shares for $131,538Director Francesco Bianchi sold 1,650 ordinary shares on Aug. 31, 2026 at $79.72.Direct holdings fell to 7,934 ordinary shares follow","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDLsNS2b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"LivaNova Director Francesco Bianchi Sells 1,650 Shares for $131,538","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIVN","LU2065171311.SGD","LU2065170008.USD","BK4082","LU2065169927.USD","LFSC","LU2065171402.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}